These favorable metabolic effects of TMZ could be explained by the findings of Zhang et al. who demonstrated that TMZ treatment in a non‐alcoholic fatty liver disease mouse model alleviated hyperlipidemia, glucose intolerance and hepatic steatosis via the upregulation of AMP‐activated protein kinase (AMPK)- forkhead box O1 (FOXO1) pathway27. The gene discussed is FOXO1; the disease is alcoholic fatty liver disease.